SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will officially launch a $125 million Series B funding round at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA January 12-15.

SonoThera is a biotechnology company dedicated to treating the root cause of human diseases through developing the next generation of genetic medicines. Our nonviral technology is designed to overcome all prevailing limitations of genetic medicine, enabling a pipeline of products which leverages our novel capabilities. Using ultrasound-mediated delivery (UMD), we are developing a proprietary, non-invasive approach which enables broad, highly targeted biodistribution, delivery of diverse genetic payloads without size restriction, in a redosable manner designed to be safe, well-tolerated and cost-effective.